Researchers have discovered that the TLR5 agonist Entolimod (CBLB502, Cleveland BioLabs Inc.), which is in development as a radioprotective agent, work primarily on receptors in the liver, and that it may be useful to fight liver metastases and, more broadly, as a liver-protective agent.